Feedback PLC Trading update (0173X)
25 April 2019 - 8:00AM
UK Regulatory
TIDMFDBK
RNS Number : 0173X
Feedback PLC
25 April 2019
The information contained within this announcement is deemed by
the Company to constitute inside information as stipulated under
the Market Abuse Regulations (EU) No. 596/2014. Upon the
publication of this announcement via Regulatory Information
Service, this inside information is now considered to be in the
public domain
Feedback plc
Trading update
Cambridge, 25 April 2019: Feedback plc (AIM: FDBK, "Feedback" or
the "Company"), the specialist medical imaging technology company,
announces a trading update for the financial year ending 31 May
2019.
Following new hires and investment in product sales in the first
half of the financial year, it is anticipated that Feedback will
report significant growth in recognised revenue for the year ending
31 May 2019.
The investment in new hires for Cadran, along with the agreement
with Future Processing, signed in January 2019, to accelerate
Feedback Medical's technology development and innovation, has
increased the Company's cost base, the principal benefit of which
will not be realised until the next financial year. As a result,
the loss for the current financial year will reflect such
investment but not the total anticipated income.
As announced in the half year results in January 2019, these
investments have been made in order to help drive sales, increase
capabilities and improve functionality of Feedback's technology as
well as to provide access to specialist medical imaging and AI
expertise.
As announced on 9 April 2019, with the appointment of Dr Tom
Oakley as the new CEO of the Company, a strategic review of the
business is currently underway. A further announcement will be made
in due course.
-Ends-
Enquiries:
Feedback plc +44 (0)1954 718072
Tom Oakley, CEO IR@fbk.com
Lindsay Melvin, CFO
Allenby Capital Limited (Nominated Adviser)
David Worlidge / Asha Chotai +44 (0)20 3328 5656
Peterhouse Corporate Finance Ltd (Joint
Broker)
Lucy Williams / Duncan Vasey +44 (0)20 7469 0936
Stanford Capital Partners Limited (Joint +44 20 3815 8880
Broker)
Patrick Claridge / John Howes +44 (0)20 7457 2020
feedbackplc@instinctif.com
Instinctif Partners
Rozi Morris/ Deborah Bell/ Phillip Marriage
Notes to editors
About Feedback plc
Feedback plc (AIM: FDBK) is a specialist medical imaging
technology company providing innovative software and systems,
through its fully-owned trading subsidiary, Feedback Medical
Limited. Its products advance the work of radiologists, clinicians
and medical researchers by improving workflows and giving unique
insights into diseases, particularly cancer. Feedback Medical works
with customers globally from headquarters in the internationally
renowned scientific hub of Cambridge, UK. Its proprietary
technologies are TexRAD(R) , the quantitative texture analysis tool
and Cadran, a picture archiving communication system (PACS). For
more information, see www.fbk.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
TSTDGGDSSGDBGCS
(END) Dow Jones Newswires
April 25, 2019 02:00 ET (06:00 GMT)
Feedback (LSE:FDBK)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Feedback (LSE:FDBK)
Historical Stock Chart
Von Jul 2023 bis Jul 2024